Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.45 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.45 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL232706 | 0.86 | — | — | |
| SCHEMBL14392990 | 0.81 | ALDH1A1 (0.43) | ALDH1A1CYP1A2CYP2D6MAPTCYP2C9 | |
| SCHEMBL18075667 | 0.79 | CYP1A2 (0.39) | ALDH1A1CYP1A2CYP2D6MAPTCYP2C9 | |
| SCHEMBL11908759 | 0.78 | LMNA (0.64) | ALDH1A1CYP1A2CYP2D6MAPTCYP2C9 | |
| SCHEMBL965544 | 0.77 | ALDH1A1 (0.54) | ALDH1A1CHRNB2CHRNB4CHRNA4HSD17B10 | |
| SCHEMBL131476 | 0.77 | ALDH1A1 (0.74) | ALDH1A1CHRNB2CHRNB4CHRNA4ALOX5 | |
| SCHEMBL5948495 | 0.77 | ALDH1A1 (0.74) | ALDH1A1CHRNB2CHRNB4CHRNA4HSD17B10 | |
| SCHEMBL3189950 | 0.75 | ALDH1A1 (0.70) | ALDH1A1CHRNB2CHRNB4CHRNA4LMNA | |
| SCHEMBL25416800 | 0.74 | MAPT (0.47) | ALDH1A1CYP1A2CYP2D6MAPTCYP2C9 | |
| SCHEMBL1415148 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4683672-A1 | BIOACTIVE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | Beone Medicines I GmbH (CH) | 2026-01-28 | — | — | EP | disclosed |
| US-20260007761-A1 | Bioactive Conjugate, Preparation Method Therefor and Use Thereof | BEONE MEDICINES I GMBH (CH) | 2026-01-08 | — | — | US | disclosed |
| WO-2024194851-A1 | BIOACTIVE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | BEIGENE SWITZERLAND GMBH (CH) | 2024-09-26 | — | — | WO | disclosed |
| CN-112516179-A | Dosing regimens and formulations for adenovirus type B | 普赛奥克苏斯治疗公司 | 2021-03-19 | — | — | CN | disclosed |
| US-10727488-B2 | Redox mediators for metal-sulfur batteries | THE MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2020-07-28 | — | — | US | disclosed |
| US-10727488-B2 | Redox mediators for metal-sulfur batteries | THE MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2020-07-28 | — | — | US | disclosed |
| US-20180116983-A1 | COMPOUNDS FOR TREATING DISORDERS ASSOCIATED WITH BK CHANNEL MODULATION | CANBEX THERAPEUTICS LIMITED (GB) | 2018-05-03 | — | — | US | disclosed |
| US-20180116983-A1 | COMPOUNDS FOR TREATING DISORDERS ASSOCIATED WITH BK CHANNEL MODULATION | CANBEX THERAPEUTICS LIMITED (GB) | 2018-05-03 | — | — | US | disclosed |
| US-9908843-B2 | Benzamide derivatives useful in the treatment of muscular disorders and pain and for controlling spasticity and tremors | CANBEX THERAPEUTICS LIMITED (GB) | 2018-03-06 | — | — | US | disclosed |
| US-9908843-B2 | Benzamide derivatives useful in the treatment of muscular disorders and pain and for controlling spasticity and tremors | CANBEX THERAPEUTICS LIMITED (GB) | 2018-03-06 | — | — | US | disclosed |
| US-20170222226-A1 | REDOX MEDIATORS FOR METAL-SULFUR BATTERIES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2017-08-03 | — | — | US | disclosed |
| US-20170222226-A1 | REDOX MEDIATORS FOR METAL-SULFUR BATTERIES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2017-08-03 | — | — | US | disclosed |
| US-20170222226-A1 | REDOX MEDIATORS FOR METAL-SULFUR BATTERIES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2017-08-03 | — | — | US | disclosed |
| US-20160304441-A1 | BENZAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF MUSCULAR DISORDERS AND PAIN AND FOR CONTROLLING SPASTICITY AND TREMORS | UCL BUSINESS PLC (GB) | 2016-10-20 | — | — | US | disclosed |
| US-20160304441-A1 | BENZAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF MUSCULAR DISORDERS AND PAIN AND FOR CONTROLLING SPASTICITY AND TREMORS | UCL BUSINESS PLC (GB) | 2016-10-20 | — | — | US | disclosed |
| WO-2016128771-A1 | COMPOUNDS FOR TREATING DISORDERS ASSOCIATED WITH BK CHANNEL MODULATION | CANBEX THERAPEUTICS LIMITED (GB) | 2016-08-18 | — | — | WO | disclosed |
| CN-105793237-A | Benzamide derivatives for the treatment of muscular disorders and pain and for the control of spasticity and tremors | 坎贝克斯治疗有限公司 | 2016-07-20 | — | — | CN | disclosed |
| WO-2016025467-A1 | REDOX MEDIATORS FOR METAL-SULFUR BATTERIES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-02-18 | — | — | WO | disclosed |
| WO-2016025467-A1 | REDOX MEDIATORS FOR METAL-SULFUR BATTERIES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-02-18 | — | — | WO | disclosed |
| WO-2015082938-A1 | BENZAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF MUSCULAR DISORDERSAND PAIN AND FOR CONTROLLING SPASTICITY AND TREMORS | CANBEX THERAPEUTICS LIMITED (GB) | 2015-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260007761-A1 | Bioactive Conjugate, Preparation Method Therefor and Use Thereof | IGLV6-57, BCR, INCENP | ALDH1A1 2110/4885CHRNB2 426/4885CHRNB4 803/4885 |
| US-10727488-B2 | Redox mediators for metal-sulfur batteries | SQOR, NDUFS4, NDUFS3 | ALDH1A1 1024/4885CHRNB2 3329/4885CHRNB4 2892/4885 |
| US-20170222226-A1 | REDOX MEDIATORS FOR METAL-SULFUR BATTERIES | SQOR, NDUFS4, NDUFS3 | ALDH1A1 1024/4885CHRNB2 3329/4885CHRNB4 2892/4885 |
| US-20180116983-A1 | COMPOUNDS FOR TREATING DISORDERS ASSOCIATED WITH BK CHANNEL MODULATION | HCN4, KCNJ4, KCNQ4 | ALDH1A1 3891/4885CHRNB2 199/4885CHRNB4 120/4885 |
| US-20160304441-A1 | BENZAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF MUSCULAR DISORDERS AND PAIN AND FOR CONTROLLING SPASTICITY AND TREMORS | MUSK, MYLK2, CBR3 | ALDH1A1 3265/4885CHRNB2 94/4885CHRNB4 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.